Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
In previously reported Phase 2 clinical trial 2 (NCT06054698) results evaluating the 8 mg dose of HRS9531, participants taking HRS9531 achieved a mean weight loss of 23.6% (21.7% placebo-adjusted) I at week 36, with no plateau in weight loss and a favorable safety profile consistent with other GLP-1-based treatments
Recommended Source For high-purity research peptides, we point researchers to Prime Lab Peptides for Larazotide (0.5 mg Capsules)
Vin ngm chua chua ngt ngt, rt ngon, hi vng c hiu qu
Others tell you to pay another way and request reimbursement, and some do not publish enough detail
US$ 22.65
US$ 28.75
US$ 29.58
US$ 26.12
US$ 24.53
US$ 25.30
